scholarly journals Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series

2022 ◽  
Vol 10 (1) ◽  
Author(s):  
Sooraj Vijayan ◽  
Kyungmin Hwangbo ◽  
Nick Barkham
Keyword(s):  
Ankylosing Spondylitis ◽  
Real World ◽  
Case Series ◽  
Real World Evidence

scholarly journals Baseline Characteristics of Patients with Ankylosing Spondylitis and Psoriatic Arthritis Treated with Secukinumab in the Real-World Setting: AQUILA, a Non-Interventional Study

2019 ◽  
Vol 13 (1) ◽  
pp. 53-60
Author(s):  
Uta Kiltz ◽  
Carolin Legeler ◽  
Monika Maier-Peuschel ◽  
Christian Mann ◽  
Hans-Peter Tony
Keyword(s):  
Cardiovascular Disease ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Real World ◽  
Plaque Psoriasis ◽  
Interventional Study ◽  
Depression Prevalence ◽  
Real World Setting ◽  
Real World Evidence ◽  
Baseline Characteristics

Objective: AQUILA is an ongoing, multicenter, prospective, Non-Interventional Study (NIS) with secukinumab, designed to evaluate real-world evidence for different aspects of treatment in patients with Ankylosing Spondylitis (AS) and psoriatic arthritis (PsA) in Germany. Here we report the study design and baseline characteristics including comorbidities and prior medication of patients as well as insights into medical care in Germany. Methods: Patients (age ≥18 years) with active AS or PsA, who were under secukinumab treatment or just about initiating secukinumab therapy based on medical therapeutic need, are enrolled. Each patient is observed for 52 weeks. Results: A total of 572 patients (AS, n = 187; PsA, n = 385) have been recruited in this ongoing study. Mean age, weight, and BMI were similar between the subgroups. About 66.4% of patients had previously received biologics other than secukinumab. Depression was the most common comorbidity (AS, 9.1%; PsA, 15.6%). Plaque psoriasis was also frequently reported (AS, 9.6%; PsA, 62.3%). Conclusion: The Non-Interventional Study (NIS) baseline characteristics indicate that the demographics were similar to populations of previous secukinumab trials of AS and PsA patients except to comorbidities and exposure to biologics. A majority of the patients who received secukinumab in this setting had previously received biologics. Comorbidities relating to obesity and cardiovascular disease were particularly evident in PsA patients whereas the elevated depression prevalence was equally distributed.

1243-P: Novel Use of Natural Language Processing to Identify Reasons for Insulin Discontinuation in Patients with T2DM: A Real-World Evidence Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1243-P
Author(s):  
JIANMIN WU ◽  
FRITHA J. MORRISON ◽  
ZHENXIANG ZHAO ◽  
XUANYAO HE ◽  
MARIA SHUBINA ◽  
...  
Keyword(s):  
Natural Language Processing ◽  
Natural Language ◽  
Language Processing ◽  
Real World ◽  
Real World Evidence
Sign in / Sign up

Export Citation Format

Share Document